ARCHIVES

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Phase III Kyprolis Trial Fails OS Primary Endpoint

August 29, 2014

ASCO Proposes Two IOM Workshops On Changing Clinical Trials Group System

September 17, 2010

Cancer Control Survey “a Flop,” Advisory committee Members Say

October 11, 1974

SAIC Begins Transition Of Frederick Operations From Incumbent PRI

March 17, 1995

DCT Moves Fast to Take Control Of Cooperative Groups, Get Multimodality Studies Under Way

October 3, 1975

The White House: Justice Department May Sue Tobacco Firms, Clinton Says

January 22, 1999